Capricor Therapeutics Inc
NASDAQ:CAPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
US |
|
Schaeffler AG
F:SHAU
|
DE |
|
P
|
Pierre et Vacances SA
F:PV6
|
FR |
|
Easterly Government Properties Inc
F:E050
|
US |
|
H
|
Hysan Development Co Ltd
XMUN:HYN
|
HK |
|
B
|
Bank of Nova Scotia
XMUN:BKN
|
CA |
|
A
|
Automatic Data Processing Inc
XMUN:ADP
|
US |
|
M
|
Mitsubishi Estate Co Ltd
F:MES
|
JP |
|
Global Dominion Access SA
F:G08
|
ES |
|
O
|
Olin Corp
F:OLN
|
US |
|
F
|
Fortive Corp
F:F03
|
US |
|
B
|
Bank of Nova Scotia
F:BKN
|
CA |
|
Edenred SE
PAR:EDEN
|
FR |
|
Madison Technologies Inc
OTC:MDEX
|
CA |
|
Sumitomo Electric Industries Ltd
F:SMO
|
JP |
|
K
|
Kawasaki Heavy Industries Ltd
DUS:KHE
|
JP |
|
Leonardo SpA
F:FMN
|
IT |
|
Kbc Groep NV
F:KDB
|
BE |
|
Disco Corp
F:D650
|
JP |
|
China High Speed Transmission Equipment Group Co Ltd
F:BGR
|
KY |
|
T3 Defense Inc
NASDAQ:DFNS
|
US |
|
Moelis & Co
NYSE:MC
|
US |
|
P
|
Propel Global Bhd
KLSE:PGB
|
MY |
|
Celsius Resources Ltd
ASX:CLA
|
AU |
Intrinsic Value
Is CAPR undervalued or overvalued?
See the intrinsic value estimate for Capricor Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
CAPR looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with CAPR’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Capricor Therapeutics Does
Capricor Therapeutics is a biotechnology company that develops cell-based medicines for serious diseases, with a main focus on heart and muscle disorders. Its lead program is deramiocel, an allogeneic cardiosphere-derived cell therapy being studied for Duchenne muscular dystrophy, a genetic disease that weakens muscles over time. The company also works on exosome-based therapies, which use tiny particles released by cells as a way to deliver treatment signals.
- Headquarters
- United States of America US
- Employees
- 231
- IPO date
- Jun 4, 2002
Capricor Therapeutics has no economic moat
Capricor Therapeutics Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Revenue & Expenses Breakdown
Capricor Therapeutics Inc
Earnings Waterfall
Capricor Therapeutics Inc
The intrinsic value for Capricor Therapeutics Inc (CAPR) under the Base Case is hidden USD.
Compared with the current market price of 5.74 USD, the stock appears hidden.